BeyondSpring Financials
BYSI Stock | USD 1.89 0.04 2.16% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 3.7 | 2.3145 |
|
|
Investors should never underestimate BeyondSpring's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor BeyondSpring's cash flow, debt, and profitability to make informed and accurate decisions about investing in BeyondSpring.
Net Income |
|
BeyondSpring | Select Account or Indicator |
Understanding current and past BeyondSpring Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of BeyondSpring's financial statements are interrelated, with each one affecting the others. For example, an increase in BeyondSpring's assets may result in an increase in income on the income statement.
BeyondSpring Stock Summary
BeyondSpring competes with Surrozen, Armata Pharmaceuticals, Pasithea Therapeutics, Oncternal Therapeutics, and Aditxt. BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company was founded in 2010 and is headquartered in New York, New York. Beyondspring operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 103 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | KYG108301006 |
CUSIP | G10830100 |
Location | New York; U.S.A |
Business Address | 100 Campus Drive, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | beyondspringpharma.com |
Phone | (646) 305 6387 |
Currency | USD - US Dollar |
BeyondSpring Key Financial Ratios
Return On Equity | -3.1 | ||||
Operating Margin | (7.42) % | ||||
Price To Sales | 39.74 X | ||||
Revenue | 1.75 M | ||||
Gross Profit | 1.35 M |
BeyondSpring Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 44.6M | 117.0M | 81.6M | 46.2M | 24.8M | 41.9M | |
Other Current Liab | 65K | 7.8M | 10.0M | 3.0M | 4.2M | 4.1M | |
Net Tangible Assets | (7.8M) | 30.3M | 88.3M | 26.7M | 30.7M | 24.2M | |
Net Debt | (32.0M) | (105.2M) | (38.1M) | (29.4M) | (3.8M) | (4.0M) | |
Retained Earnings | (216.8M) | (277.8M) | (342.0M) | (375.3M) | (396.3M) | (376.5M) | |
Accounts Payable | 2.5M | 2.2M | 1.7M | 1.1M | 1.4M | 2.5M | |
Cash | 35.9M | 109.5M | 41.6M | 34.4M | 7.8M | 7.4M | |
Other Current Assets | 410K | 3.9M | 1.0M | 1.3M | 10.6M | 11.1M | |
Total Liab | 13.4M | 30.4M | 60.7M | 49.2M | 48.3M | 26.2M | |
Total Current Assets | 40.9M | 113.4M | 75.1M | 38.5M | 18.4M | 17.5M | |
Other Assets | 946K | 1.3M | 3.1M | 1.0 | 1.15 | 1.09 | |
Net Invested Capital | 31.7M | 90.5M | 28.3M | (6.0M) | (26.8M) | (25.5M) | |
Net Working Capital | 30.8M | 99.6M | 60.0M | 31.2M | 10.5M | 9.9M |
BeyondSpring Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 71K | 206K | 85K | 87K | 17K | 0.0 | |
Operating Income | (40.3M) | (64.2M) | (66.2M) | (37.2M) | (23.1M) | (24.3M) | |
Ebit | (40.3M) | (63.7M) | (64.6M) | (36.1M) | (21.8M) | (22.9M) | |
Research Development | 31.3M | 41.8M | 36.9M | 25.6M | 14.6M | 13.9M | |
Ebitda | (40.0M) | (63.7M) | (64.5M) | (35.0M) | (21.5M) | (22.6M) | |
Income Before Tax | (40.3M) | (63.8M) | (64.6M) | (36.1M) | (21.8M) | (22.9M) | |
Net Income | (38.3M) | (61.1M) | (68.2M) | (36.3M) | (21.0M) | (22.1M) | |
Income Tax Expense | (2.0M) | (2.8M) | 3.6M | 163K | 106K | 111.3K | |
Minority Interest | 854K | 3.5M | 4.0M | 3.0M | 922K | 1.5M | |
Interest Income | 184K | 116K | 98K | 195K | 421K | 442.1K | |
Net Interest Income | (22K) | 31K | 11K | 178K | 421K | 442.1K |
BeyondSpring Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change To Inventory | (3.3M) | 1.0M | 1.8M | 1.2M | 186K | 195.3K | |
Investments | (4K) | (52K) | (20.4M) | 17.6M | (100K) | (105K) | |
Change In Cash | 32.0M | 73.6M | (67.9M) | (7.2M) | (16.6M) | (15.8M) | |
Free Cash Flow | (48.2M) | (43.8M) | (50.1M) | (27.5M) | (16.6M) | (17.4M) | |
Other Non Cash Items | 9.9M | 659K | 546K | 509K | 772K | 733.4K | |
Capital Expenditures | 4K | 52K | 2.8M | 34K | 100K | 95K | |
Net Income | (40.3M) | (63.8M) | (68.2M) | (36.3M) | (21.0M) | (22.1M) | |
End Period Cash Flow | 35.9M | 109.5M | 41.6M | 34.4M | 17.8M | 32.3M | |
Change To Netincome | 3.6M | (147K) | 6.0M | (1.5M) | (1.4M) | (1.3M) |
BeyondSpring Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BeyondSpring's current stock value. Our valuation model uses many indicators to compare BeyondSpring value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BeyondSpring competition to find correlations between indicators driving BeyondSpring's intrinsic value. More Info.BeyondSpring is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . As of now, BeyondSpring's Return On Equity is increasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BeyondSpring's earnings, one of the primary drivers of an investment's value.BeyondSpring Systematic Risk
BeyondSpring's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. BeyondSpring volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on BeyondSpring correlated with the market. If Beta is less than 0 BeyondSpring generally moves in the opposite direction as compared to the market. If BeyondSpring Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one BeyondSpring is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of BeyondSpring is generally in the same direction as the market. If Beta > 1 BeyondSpring moves generally in the same direction as, but more than the movement of the benchmark.
BeyondSpring Thematic Clasifications
BeyondSpring is part of Cancer Fighters investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases
This theme covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. Get More Thematic Ideas
Cancer Fighters | View |
Today, most investors in BeyondSpring Stock are looking for potential investment opportunities by analyzing not only static indicators but also various BeyondSpring's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of BeyondSpring growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
BeyondSpring November 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of BeyondSpring help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of BeyondSpring. We use our internally-developed statistical techniques to arrive at the intrinsic value of BeyondSpring based on widely used predictive technical indicators. In general, we focus on analyzing BeyondSpring Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build BeyondSpring's daily price indicators and compare them against related drivers.
Information Ratio | (0.05) | |||
Maximum Drawdown | 15.1 | |||
Value At Risk | (6.36) | |||
Potential Upside | 5.24 |
Complementary Tools for BeyondSpring Stock analysis
When running BeyondSpring's price analysis, check to measure BeyondSpring's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeyondSpring is operating at the current time. Most of BeyondSpring's value examination focuses on studying past and present price action to predict the probability of BeyondSpring's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeyondSpring's price. Additionally, you may evaluate how the addition of BeyondSpring to your portfolios can decrease your overall portfolio volatility.
CEOs Directory Screen CEOs from public companies around the world | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |